Fig. 4

T-BsAbs drive T cell infiltration, activation, and function in PDAC (A) Treatment of SW1990 tumor-bearing mice with EGFR and HER2 T-BsAbs; 3 × 10⁶ cells of SW1990 were subcutaneously implanted into mice. Once tumor reached ∼500mm³, mice received a single infusion of 2 × 10⁷ T cells and were treated with 10µg T-BsAb, administered twice per week. Tumors were harvested for analysis on day 10 after initiation of treatment. Mice that exhibited 50% or more reduction in tumor volume by day 10 were excluded from this and subsequent analyses. (B) Flow cytometric analysis of the in vivo effect of T-BsAb treatments on T cell infiltration into harvested SW1990 PDAC tumors. Infiltrating T cells were identified by detection of human CD45⁺ and human CD4⁺ or CD8⁺. (C) Frequency of T cell activation indicated by detection of IFN-γ⁺TNF-α⁺ T cells and expression of CD69 among CD4⁺ or CD8⁺ T cells. (D) Frequency of CD11b⁺ intratumoral myeloid cells and prevalence of PDL1 expression